Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participants

Inclusion Criteria: * Participant has a body mass index (BMI) range of 17.6 to 26.4 kg/m\^2 inclusive and weighs at least 50 kg at screening. * Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 30 days after Investigational Product (IP) administration. * Male participant must not donate sperm during the treatment period and for 30 days after IP administration. * Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 30 days after IP administration. * Participant agrees not to participate in another interventional study while participating in the present study. Exclusion Criteria: * Participant has received any investigational therapy within 12 weeks prior to screening. * Participant has any condition that makes the participant unsuitable for study participation. * Participant has a known or suspected hypersensitivity to ASP5354 or any components of the formulation used. * Participant has had previous exposure with ASP5354. * Participant has any of the liver function tests (alkaline phosphatase \[ALP\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and total bilirubin \[TBL\]) above the upper limit of normal (ULN) on day -1. In such a case, the assessment may be repeated once. * Participant has creatinine level outside normal limits on day -1. In such a case, the assessment may be repeated once. * Participant has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to IP administration. * Participant has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy. * Participant has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within 1 week prior to day -1. * Participant has any clinically significant abnormality following the physical examination, electrocardiogram (ECG) and protocol-defined clinical laboratory tests at screening or on day -1. * Participant has a mean pulse \< 40 or \> 100 bpm; mean systolic blood pressure (SBP) \< 90 or \> 140 mmHg; mean diastolic blood pressure (DBP) \< 40 or \> 90 mmHg (measurements taken in triplicate after participant has been resting in the supine position for at least 5 minutes; pulse will be measured automatically) on day-1. If the mean blood pressure exceeds the limits above, one additional triplicate may be taken. * Participant has body temperature \< 35.0ºC or \>= 37.5ºC on day -1. * Participant has a mean corrected QT interval using Fridericia's formula (QTcF) of \> 430 msec on day -1. If the mean QTcF exceeds the limits above, one additional triplicate ECG may be taken. * Participant has used any prescribed or nonprescribed drugs (including vitamins, oral contraceptives or hormone replacement therapy (HRT) and natural and herbal remedies, e.g., St. John's Wort) in the 2 weeks prior to IP administration, except for occasional use of acetaminophen (up to 2 g/day) and topical dermatological products (including corticosteroid products). * Participant has a history of smoking \> 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to day -1. * Participant has a history of consuming \> 16 units of alcohol per week within 3 months prior to day -1 (note: 1 unit = 10 g pure alcohol, = 250 mL of beer \[5%\], 35 mL of spirits \[35%\] or 100 mL of wine \[12%\]). * Participant has used any drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or morphine and phencyclidines) within 3 months prior to day -1 or the participant tests positive for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and morphine, phencyclidines) at screening or on day -1. * Participant has used any inducer of metabolism (e.g., barbiturates and rifampin) in the 3 months prior to day -1. * Participant has had significant blood loss, donated \>= 400 mL of whole blood within 90 days, \>= 200 mL of whole blood within 30 days or donated blood components within 14 days prior to day -1 and/or received a transfusion of any blood or blood products within 60 days. * Participant has a positive serology test for hepatitis B core (HBc) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies and antigen or antibodies to human immunodeficiency virus (HIV) type 1 and/or type 2 and syphilis at screening. * Participant is an employee of Astellas, the study-related contract research organizations (CROs) or the clinical unit.